(Q37990675)

26 August 2017

title

Melatonin and mitochondrial dysfunction in the central nervous system (English)

1 reference

26 August 2017

0 references

1 reference

0 references

Daniel P Cardinali

1

1 reference

26 August 2017

Eleonora S Pagano

2

1 reference

26 August 2017

Pablo A Scacchi Bernasconi

3

1 reference

26 August 2017

Roxana Reynoso

4

1 reference

26 August 2017

Pablo Scacchi

5

1 reference

26 August 2017

publication date

25 February 2012

1 reference

26 August 2017

published in

Hormones and Behaviour

1 reference

26 August 2017

volume

63

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

322-330

1 reference

Melatonin-mitochondria interplay in health and disease.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Effect of melatonin implants on gonadal weights and pineal gland fine structure of the golden hamster

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin as a cytoskeletal modulator: implications for cell physiology and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondrial involvement in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Assessing mitochondrial dysfunction in cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Binding of Melatonin to Human and Rat Plasma Proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Clinical aspects of melatonin intervention in Alzheimer's disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin and its analogs in insomnia and depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Interactions of melatonin with membrane models: portioning of melatonin in AOT and lecithin reversed micelles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Role of mitochondrial amyloid-beta in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

The basic physiology and pathophysiology of melatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Protective effect of melatonin on cellular energy depletion mediated by peroxynitrite and poly (ADP-ribose) synthetase activation in a non-septic shock model induced by zymosan in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Stimulatory effects of melatonin on ependymal epithelium of choroid plexuses in golden hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondrial disorders in the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Differential effects of melatonin on amyloid-beta peptide 25-35-induced mitochondrial dysfunction in hippocampal neurons at different stages of culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Antiinflammatory activity of melatonin in central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin as a natural ally against oxidative stress: a physicochemical examination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mild cognitive impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

The mitochondrial production of reactive oxygen species in relation to aging and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Neuronal calcium homeostasis and dysregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondria--a nexus for aging, calorie restriction, and sirtuins?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Antioxidative Protection by Melatonin: Multiplicity of Mechanisms from Radical Detoxification to Radical Avoidance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin: signaling mechanisms of a pleiotropic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Circadian rhythms, oxidative stress, and antioxidative defense mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin--a pleiotropic, orchestrating regulator molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin attenuates amyloid beta25-35-induced apoptosis in mouse microglial BV2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

24-Hour variation in gene expression of redox pathway enzymes in rat hypothalamus: effect of melatonin treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Renal toxicity of the carcinogen delta-aminolevulinic acid: antioxidant effects of melatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin inhibits amphetamine-induced increase in alpha-synuclein and decrease in phosphorylated tyrosine hydroxylase in SK-N-SH cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondrial calcium and the permeability transition in cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Structure and organization of mitochondrial respiratory complexes: a new understanding of an old subject

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin attenuates arsenite-induced apoptosis in rat brain: involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of alpha-synuclein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mechanism of the peroxidase activity of Cu, Zn superoxide dismutase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Nitric oxide, hypoxia and brain inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondrial superoxide: a key player in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Tissue retention and subcellular distribution of continuously infused melatonin in rats under near physiological conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Techniques to investigate neuronal mitochondrial function and its pharmacological modulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Rhythms of glutathione peroxidase and glutathione reductase in brain of chick and their inhibition by light

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin prevents age-related mitochondrial dysfunction in rat brain via cardiolipin protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Calcium-dependent mitochondrial function and dysfunction in neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondria, oxygen free radicals, disease and ageing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Effect of melatonin treatment on oxygen consumption by rat liver mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondrial dysfunction and psychiatric disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Regulation of antioxidant enzymes: a significant role for melatonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin and cell death: differential actions on apoptosis in normal and cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Misfolded proteins and neurodegeneration: role of non-native cytochrome c in cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Therapeutic prospects for mitochondrial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin in mitochondrial dysfunction and related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Free radical-mediated oxidation of free amino acids and amino acid residues in proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Both physiological and pharmacological levels of melatonin reduce DNA adduct formation induced by the carcinogen safrole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Parkinson's disease: genetic versus toxin-induced rodent models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Influence of aging on membrane permeability transition in brain mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Bioavailability of oral melatonin in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Impaired balance of mitochondrial fission and fusion in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Reduced oxidative damage in ALS by high-dose enteral melatonin treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin protection against lethal myocyte injury induced by doxorubicin as reflected by effects on mitochondrial membrane potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin Treatment for Age-Related Insomnia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YHBEH.2012.02.020

10.1016/J.YHBEH.2012.02.020

7 January 2021

Identifiers

DOI

1 reference

26 August 2017

1 reference